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CaTOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial) was a multinational
clinical trial of 3,445 heart failure with preserved ejection fraction patients that enrolled in 233 sites in 6 countries in North
America, Eastern Europe, and South America. Patients with a heart failure hospitalization in the last 12 months or an
elevated B-type natriuretic peptide were randomized to the mineralocorticoid receptor antagonist spironolactone versus
placebo. Sites in Russia and the Republic of Georgia provided the majority of early enrollment, primarily based on the
hospitalization criterion because B-type natriuretic peptide levels were initially unavailable there. With the emergence of
country-speciﬁc aggregate event rate data indicating lower rates in Eastern Europe and differences in patient characteristics
there, the Data Safety and Monitoring Board recommended relatively increasing enrollment in North America plus other
corrective measures. Although ﬁnal enrollment reﬂected the increased contribution from North America, a plurality of the
ﬁnal cohort came from Russia and Georgia (49% vs. 43% in North America). B-type natriuretic peptide measurements from
Russia and Georgia, available later in the trial, suggested no or a mild level of heart failure consistent with low event rates.
The primary results showed no signiﬁcant spironolactone treatment effect overall (primary endpoint hazard ratio [HR]:
0.89; 95% conﬁdence interval [CI]: 0.77 to 1.04), with a signiﬁcant hazard ratio in North and South America (HR: 0.82;
95% CI: 0.69 to 0.98; p ¼ 0.026) but not in Russia and Georgia (HR: 1.10; 95% CI: 0.79 to 1.51; interaction p ¼ 0.12).
This report describes the Data Safety and Monitoring Board’s detection and management recommendations for regional
differences in patient characteristics in TOPCAT and suggests methods of surveillance and corrective actions that may
be useful for future trials. (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial
[TOPCAT]; NCT00094302) (J Am Coll Cardiol Basic Trans Science 2016;1:180–9) ©2016TheAuthors.PublishedbyElsevier
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AB BR EV I A T I O N S
AND ACRONYM S
BNP = B-type natriuretic
peptide
CI = conﬁdence interval
DSMB = Data Safety and
Monitoring Board
HF = heart failure
HFpEF = heart failure
preserved ejection fraction
HR = hazard ratio
NT-proBNP = N-terminal
pro–B-type natriuretic peptide
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181C ountry- or region-speciﬁc differences in out-comes are frequently observed in multina-tional clinical trials (1–3) and may or may
not be indicative of true differences in drug response
(4). Geographies may vary with respect to genetics
(4,5); nongenetic racial characteristics (5,6); medical
practice, training, or infrastructure patterns that
may inﬂuence outcomes despite general adherence
to a clinical trial protocol (4); and other factors. In
the planning and conduct of multinational clinical tri-
als, the potential impact of geographic differences in
outcomes is among many important factors that
needs to be considered, but often is not taken into ac-
count (4).
The TOPCAT (Treatment of Preserved Cardiac
Function Heart Failure With an Aldosterone Antago-
nist Trial) (7,8) was a large-scale, multinational
National Heart, Lung, and Blood Institute (NHLBI)-
sponsored clinical trial conducted in 233 sites in 6
countries located in 3 distinct geographic regions:
North America (United States and Canada); Eastern
Europe (Russia and the Republic of Georgia); and
South America (Argentina and Brazil). The target
disease indication investigated, heart failure with
preserved ejection fraction (HFpEF) of the left
ventricle, has been a challenge to deﬁne and enroll in
clinical trials and has thus far eluded the develop-
ment of deﬁnitive therapy (9,10). The TOPCAT Data
and Safety Monitoring Board (DSMB) worked closely
with the NHLBI, Trial Executive/Steering Committee
and the Data/Clinical Coordinating Center to deal
with several major challenges during the trial. In this
report we attempt to provide insight into regional
heterogeneity issues in TOPCAT, including how they
were detected and the recommendations made by the
DSMB to resolve them. Based on this experience we
offer suggestions for DSMB oversight of potential
geographic disparities in future multinational trials.
METHODS
DSMB ORGANIZATION. The TOPCAT DSMB organi-
zation and responsibilities are given in the
Supplemental Appendix.
DATABASE. The database consisted of Clinical Trial
Coordinating Center reports provided to the open and
closed sessions of the various DSMB meetings, the
meeting minutes, monthly safety reports viewed byArmetheon Inc. Dr. Boineau was previously employed by the National Hea
DSMB nonvoting executive secretary. Dr. Greenberg is a consultant for Nova
Relypsa, and ZS. All other authors have reported that they have no relationsh
Manuscript received February 23, 2016; accepted March 2, 2016.the DSMB chair, correspondence of the chair
with the NHLBI, and published data from the
entire TOPCAT cohort (8,11). Interval enroll-
ment data were the most recent ﬁgures
available at the various reviews or from more
extensive “data freeze” analyses performed
within 2 months of the meetings.
STATISTICAL METHODOLOGY. Analyses
were as described for the TOPCAT trial
(7,8,11) using an unadjusted model. Addi-
tional analyses were conducted using
chi-square/contingency table tests with a
Bonferroni correction.TOPCAT TRIAL
OVERVIEW. The TOPCAT trial enrolled 3,445 patients
with HFpEF between August 10, 2006, and January
31, 2012, with a mean follow-up of 3.3 years ending on
June 30, 2013. Overall (8) and regional (8,11) differ-
ences in outcomes have been previously reported.
The primary endpoint of TOPCAT was the composite
of time to cardiovascular death, aborted cardiac
arrest, or HF hospitalization, with each component
adjudicated by a clinical events committee. Inclusion
of non-U.S. sites was an integral part of the original
study design to enhance generalizability of the
results and manage trial costs.
In addition to monthly safety monitoring that was
focused on the class-adverse effects of mineralocor-
ticoid receptor antagonists (MRAs) or MRAs in com-
bination with other renin-angiotensin system
inhibitors (hyperkalemia, renal function, gyneco-
mastia in each blinded treatment arm), at its sched-
uled meetings, the DSMB monitored overall
enrollment, the aggregate (both treatment groups
combined) event rate, and country-speciﬁc data.
Throughout the trial, the DSMB elected not to
disclose the observed aggregate event rate to the
Executive/Steering Committee, but to report to them
any important departure from the pre-trial assump-
tion expected rate that might affect statistical power.
The interim analysis plan included a DSMB review of
unblinded primary outcome data by treatment arm
at 33%, 50%, and 75% of the expected number of
primary endpoints, using events conﬁrmed by the
clinical events committee and respective efﬁcacy
conditional power futility boundaries of #10%, #15%,rt, Lung, and Blood Institute. Dr. Rosenberg is the
rtis, Zensun, Teva, Celladon, Johnson and Johnson,
ips relevant to the contents of this paper to disclose.
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182and #20%. The trial reached completion, with 671
subjects having a primary event (8). The hazard ratios
(HR) and 95% conﬁdence intervals (CI) for the pri-
mary endpoint was 0.89 (95% CI: 0.77 to 1.04),
p ¼ 0.14 (8) and 0.83 (95% CI: 0.69 to 0.99), p ¼ 0.04
for time to HF hospitalization as a single endpoint (8).
The TOPCAT protocol deﬁned HFpEF as follows:
1) having at least 1 HF symptom present during
screening; 2) 1 HF sign present during the last 12
months; and 3) meeting criteria for 1 of 2 design
strata: at least 1 hospitalization in the last 12 months
“for which heart failure had to be a major component
of the hospitalization,” or an elevated B-type natri-
uretic peptide (BNP) or N-terminal pro–B-type natri-
uretic peptide (NT-proBNP) level sampled in the last
60 days. To exclude heart failure with reduced ejec-
tion fraction, the left ventricular ejection fraction
measured during the previous 6 months had to
be $45%. The dual hospitalization or NP qualiﬁcation
scheme for enrollment was necessary because at the
beginning of the trial BNP or NT-proBNP assays were
not universally available. For the ﬁnal cohort 28% of
patients were enrolled using NP criteria (8), 45% of
patients in North and South America and 11% in
Eastern Europe. The pre-speciﬁed subgroup analysis
of HF qualifying criteria yielded a signiﬁcant inter-
action p value of 0.01, with an NP subgroup HR of
0.65 (95% CI: 0.49 to 0.87, p ¼ 0.003) and the 5 HF
hospitalization subgroup having no evidence of
a treatment effect (HR: 1.01; 95% CI: 0.84 to 1.21;
p ¼ 0.92) (8).
Of the 981 patients enrolled by NP criteria, 81%
were from North or South America. Additional evi-
dence of geographic differences in outcomes by
country and region were noted (8,11). Patients
enrolled in Russia and Georgia had lower event rates
in the placebo arm, and in the spironolactone arm,
they showed no evidence of hyperkalemia or renal
dysfunction despite having an increased incidence of
gynecomastia plus no evidence of a treatment effect
(8,11). The HR of the primary endpoint for patients
enrolled in the Americas was 0.82 (95% CI: 0.69 to
0.98, p ¼ 0.026) compared with 1.10 (95% CI: 0.79 to
1.51, p ¼ 0.58) in Russia and Georgia (p ¼ 0.12 for
interaction between treatment and region) (8,11).
ENROLLMENT. Pre-trial plans and projections. DSMB
also served as the protocol review committee, with
the ﬁnal version of the protocol approved in January
2005. The protocol contained language on the logis-
tical and clinical research organizational support for
recruiting patients from North America, South
America, Western Europe, and Eastern Europe. DSMB
became aware of the potential for non–North Amer-
ican sites to inﬂuence the overall outcome of the trialwhen the plan to enroll a large number of patients
from Russia and the Republic of Georgia was reported
by trial leadership and the sponsor at the ﬁrst DSMB
meeting in December 2006 (Figure 1). Support for an
Eastern European strategy as a means of facilitating
recruitment was offered by the TOPCAT Steering
Committee leadership, who reported that the
CHARM-Preserved (Candesartan Cilexetil in Heart
Failure Assessment of Reduction in Mortality and
Morbidity: Clinical Study of Candesartan in Patients
With Heart Failure and Preserved Left Ventricular
Systolic Function) trial (9) “had not observed any
interaction between patient prognosis and country,”
including Russia. Nevertheless, the DSMB expressed
concern over enrolling a large number of patients
with a diagnosis of HFpEF in non–North American
sites. The DSMB-recommended strategy to deal with
this issue included the following: 1) monitoring of
source documents to check that the qualifying hos-
pitalization met the HF criterion, for which trans-
lation of source records would be needed; 2)
requesting that at a minimum, 20% of all patients
enrolled should come from North America, and the
enrollment from any 1 country should not exceed
50%; and 3) asking that enrollment rates and other
trial data be monitored by country.
The projected enrollment by region, presented by
Steering Committee leadership at the January 2008
DSMB meeting (Figure 1), is given in Figure 2 juxta-
posed against the actual ﬁnal enrollment on January
31, 2012. In the pre-trial projections, 51.1% of patients
were expected to be enrolled in Eastern Europe (42.2%
in Russia and 8.9% in Georgia), 27.8% in North
America (20.0% in the United States and 7.8% in
Canada), and 21.1% in South America (11.1% in
Argentina and 10.0% in Brazil). The ﬁnal Russia-
Georgia enrollment was close to projections, whereas
North American enrollment was higher and South
American was lower (Figure 2). The trend for enroll-
ment to favor more North American participation over
time was at the request of the DSMB, to counter the
early dominance of Eastern European enrollment.
Recru i tment dynamics . Enrollment milestones and
important trial developments are summarized in
Figure 1 and discussed in more detail in the
Supplemental Appendix. The ﬁrst patient was
enrolled in August 2006, approximately 1 year behind
schedule due primarily to delays in manufacture and
supply of study medication. In March 2007, the DSMB
was provided with the ﬁrst data available for review,
for 165 patients randomized in Russia, Georgia, and
the United States. Figure 3 shows the dominance of
Russia and Georgia in the early phases of trial
enrollment, followed by the steady ascendancy of
FIGURE 1 DSMB Reviews and Recommendations in TOPCAT
The Data and Safety Monitoring Board’s (DSMB) timeline, reviews, and recommendations (A) From December 2006 to October 1, 2010, and (B) October 27, 2010 to
September 2013 for the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial). BNP ¼ B-type natriuretic peptide; CAD ¼
coronary artery disease; CRA ¼ Clinical Research Associate; CTCC ¼ Clinical Trial Coordinating Center; HF ¼ heart failure; HFpEF ¼ heart failure with preserved ejection
fraction; NI ¼myocardial infarction; NA ¼ North America; NHLBI ¼ National Heart, Lung, and Blood Institute; NL ¼ normal limits; NP ¼ natriuretic peptide; NT-proBNP ¼
N-terminal pro–B-type natriuretic peptide; SC ¼ Steering Committee; Sx ¼ symptoms; WNL ¼ within normal limits.
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183North American randomization. At the completion of
enrollment in January 2012, the Russia and Georgia
contribution had fallen below 50% of the total, but
still constituted a plurality: North America, n ¼ 1,477
(42.9%); Russia and Georgia, n ¼ 1,678 (48.7%); and
South America, n ¼ 290 (8.4%) (Figure 3).
GEOGRAPHIC DISCREPANCIES IN RECRUITMENT
AND CLINICAL COURSE OF PATIENT POPULATIONS.
Details of the DSMB’s detection of and management
recommendations for geographic discrepancies in
the TOPCAT patient population are given in the
Supplemental Appendix, with highlights summarized
in the next section and in Figure 1.
Emergence and detect ion ; tact i ca l responses .
The ﬁrst evidence suggesting that patients from
Russia or Georgia were potentially different from
other TOPCAT regions emerged from country-speciﬁc
baseline characteristics for the ﬁrst 794 enrolled pa-
tients, presented at the January 2008 DSMB sched-
uled review (Figure 1). The data indicated that a
history of myocardial infarction or angina was more
prevalent in patients enrolled in Russia, and that
Russian and Georgian patients had less orthopnea by
history than did patients from other countries. The
signiﬁcance of these early ﬁndings was not clear at
the time, but based on subsequent developments,
these data likely reﬂected a predominance ofcoronary artery disease pathophysiology in Russia
and a lesser degree or absence of HF in Russian and
Georgian patients compared with patients from other
countries.
The ﬁrst indication that the aggregate (combina-
tion of both treatment arms) event rate was lower in
Georgia or Russia was revealed in the September
2008 closed session review (Figure 1), where based
on 1,461 total randomized patients, Georgia’s was
2.0% compared with 5.4% overall and 9.0% in the
United States. However, the number of events was
low (only 6 in Georgia and 38 in the United States).
These data were insufﬁcient for drawing ﬁrm con-
clusions, but in response, the DSMB recommended
that the trial leadership “encourage Georgian In-
vestigators to enroll patients as expected per the
study protocol.”
At the September 2008 meeting, the DSMB
approved a plan to reduce the total target enrollment
from 4,500 to 3,515 patients with 2 years of minimum
follow-up, based on the aggregate event rate being as
expected and estimated length of median follow-up
being longer, plus accepting a power calculation of
>80% as opposed to 90%. In this event-driven trial,
the new sample size calculations were based on 80%
and 85% power for 551 and 630 primary events,
respectively, assuming a 20% relative difference
FIGURE 2 TOPCAT Projected Versus Actual Enrollment by Country
TOPCAT pre-trial projected (presented to DSMB on January 30, 2008) versus actual
ﬁnal enrollment as of January 31, 2012, percentage of total for each. Abbreviations
as in Figure 1.
FIGURE 3 TOPCAT
TOPCAT actual enrol
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184between the 2 treatment arms (8). In addition, the
DSMB requested a substudy of BNP in patients
entering the trial via a history of HF hospitalization to
assess the severity of HF at baseline among the
different countries, and that the trial obtain a BNP or
NT-proBNP on every patient enrolled in Georgia and
Russia. Finally, the DSMB requested that adverseActual Enrollment by Region
lment by region, as percentage of enrollment at the sampling interval.
tes on the x-axis are either from the review data freeze or updated
mediately prior to the DSMB review. Abbreviations as in Figure 1.events, serious adverse events, and primary endpoint
event rates be presented by country at all future
meetings.
At the next DSMB review in April 2009 (Figure 1),
the country-speciﬁc unadjudicated aggregate primary
event rate patterns ﬁrst noted at the September 2008
meeting persisted and are given in Table 1. Georgia
was an outlier, with an event rate 75% lower than the
composite of all other countries (p < 0.0001) and 83%
lower than the United States (p < 0.0001). The event
rate in Russia was 35% lower than the average of
other countries (p ¼ 0.017), 56% lower than the
United States (p < 0.0001), and 2.6-fold higher than
Georgia (p ¼ 0.010). The statistical analysis of the
event rates in Table 1 is post hoc and was not per-
formed at the time of data review. However, the
lower event rate in Georgia was noted at the DSMB
review, which prompted it to recommend an increase
in enrollment of patients in the United States and
Canada in an attempt to address the circumstances in
Russia and Georgia. In March, 2010, the ﬁrst un-
blinded interim analysis was performed at 33% of the
expected primary events (Figure 1). Based on the
conditional power being above the futility threshold,
the recommendation was to continue the trial with
the current design.
In early October 2010, the NHLBI Program divi-
sional leadership managing the trial held an un-
scheduled meeting with the DSMB chair (Figure 1) to
review results of the requested BNP pilot project in
Russia and to discuss a review of source records for
the qualifying hospitalization that had been reviewed
by an NHLBI Program staff member ﬂuent in Russian.
In the vast majority (19 or 20) of the 22 reviewed
hospitalizations, ischemic symptoms rather than HF
appeared to predominate. It was noted by NHLBI
Program staff that this was consistent with ischemic
heart disease prevalence data from the I-PRESERVE
(Irbesartan in Heart Failure With Preserved Systolic
Function) (10) and EVEREST (Efﬁcacy of Vasopressin
Antagonism in Heart Failure: Outcome Study with
Tolvaptan) (12) trials. The BNP and NT-proBNP data
from Russia were compared with data from other
countries (Supplemental Table 1 and associated dis-
cussion in the Supplemental Appendix). The majority
of patients who had been enrolled via the HF hospi-
talization criteria, most of whom had NP samples
drawn after enrollment and not during the hospitali-
zation, had values within the normal range. In
contrast, very few (9%) U.S. or Canadian patients, all
of whom had NP draws done during the index hos-
pitalization, had values within the normal range. The
NT-proBNP median value for all patients entering the
trial via the hospitalization criterion in Russia or
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185Georgia was within the normal range (respectively,
233 pg/ml and 164 pg/ml), whereas it was markedly
elevated (887 pg/ml) in the United States and Cana-
dian patients. Concerns over these data were
expressed in written communication to the NHLBI,
where the DSMB chair outlined a strategy recom-
mending that the Steering Committee institute closer
monitoring of enrollment criteria for patients in both
Russia and Georgia (Supplemental Appendix).
These recommendations were accepted by the full
DSMB at the scheduled second interim analysis
meeting later in October (Figure 1), where unblinded
outcome data on 2,732 patients easily exceeded the
conditional power futility boundary (Supplemental
Appendix). During this meeting, the trial leadership
and the Clinical Trial Coordinating Center pointed out
that the BNP pilot data were subject to selection bias
because most samples in North America were ob-
tained during a HF hospitalization, as opposed to in
Russia and Georgia where NP were drawn post-
randomization after the index hospitalization.
Nevertheless, the low (208 pg/ml combined) median
values of Russian and Georgian patients were known
to be associated with low mortality or cardiovascular
hospitalization event rates in heart failure with
reduced ejection fraction (13) and were subsequently
shown to be associated with a low composite cardio-
vascular mortality and HF hospitalization rate in
HFpEF (14). Thus, although the NP data from the pilot
study did not allow a direct comparison of Eastern
European enrolled patients to those enrolled in the
Americas, they were consistent with the low primary
event rates in Russia and Georgia. After extensive
discussion of this issue, it was decided to terminate
the NP pilot study and to again emphasize to Russian
and Georgian investigators to ensure that patients
hospitalized for apparent HF met the eligibility
criteria for the trial.TABLE 1 Enrollment and Event Rate in Data Reviewed on April 13, 20
(From Data Freeze of January 30, 2009)
Final Number of
Patients Randomized
(% of Total)
Number of Patients
Randomized on January 30
2009 (%*) {%†}
United States 1,151 (33.4) 501 (29.4) {82}
Canada 326 (9.5) 137 (8.0) {60}
Russia 1,066 (30.9) 657 (38.5) {51}
Republic of Georgia 612 (17.8) 355 (20.8) {119}
Argentina 123 (3.6) 57 (3.3) {14}
Brazil 167 (4.8) 0 (0) {0}
Total 3,445 (100) 1,707 (100) {56}
Dashes indicate no possible comparison or data were not available. *Of the total trial enro
0.0125 the Bonferroni critical value.By the June 2011 review (Figure 1), 3,080 patients
had been enrolled, and for the ﬁrst time, U.S. enroll-
ment (n ¼ 1,024) exceeded any other country
(Figure 3). The previously noted country-speciﬁc dif-
ferences in baseline characteristics and event rates
persisted at this and the subsequent review in
December 2011 (Figure 1), which was conducted in
3,317 patients. At the June 2012 DSMB review
(Figure 1), full enrollment had been reached 5 months
earlier, with the United States leading recruitment at
33.4% of the total (Table 1). Relative to the projected
enrollment, the actual ﬁnal enrollment by country
was United States 167% over target, Canada 122%,
Russia 73%, Georgia 200%, Argentina 32%, and Brazil
48% (Figure 2). However, despite the overenrollment
in the United States and Canada, the 2 Eastern Euro-
pean countries enrolled 48.7% of the total, compared
with 42.9% in North America and 8.4% in South
America.
The ﬁnal interim analysis, at 75% of the projected
number of primary events, was conducted at the June
2012 review (Figure 1). Conditional power again was
well above the futility boundary (20%) and was 51%
using the observed event rates in each arm modeled
forward to the completion of follow-up, or 69% using
the observed placebo event rate but the pre-trial/
expected 20% difference in crude event rates in the
remaining patients active in the trial who had not had
a primary event. The country-speciﬁc HR and number
of events are shown in Table 2. Based on 382 patients
with conﬁrmed primary events, the overall HR was
0.792 (p ¼ 0.020, efﬁcacy boundary for stopping ¼
0.001). At this interim, an additional 161 patients had
unconﬁrmed events that were pending adjudication,
and when they were included, the HR p value was
0.118. Country-speciﬁc HR were available for the ﬁrst
time and are shown in Table 2. For the conﬁrmed
events, there was no evidence of a treatment effect in09, for 1,707 Randomized Patients
,
Number of Primary
Events
(%*) Event Rate (%)
p Value
vs. Georgia
p Value
vs. Russia
66 (50.0) 13.2 <0.0001 <0.0001
13 (9.8) 9.5 0.0004 0.11
38 (28.8) 5.8 0.010 —
8 (6.1) 2.2‡ — 0.010
7 (5.3) 12.3 0.0002 0.053
0 (0) 0 — —
132 (100) 7.7 — —
llment or events on September 16, 2008. †Of target allocation. ‡Chi-square, with p ¼
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186Georgia, but the number of primary events (n ¼ 14)
was extremely small. There was also little evidence of
a treatment effect in Russia (HR 0.95) despite 62 pri-
mary events being observed. These country-speciﬁc
HR are consistent with the ﬁnal trial outcome in
North and South America combined versus Russia
and Georgia (8,11).
TOPCAT trial follow-up was completed on June 30,
2013, and top line results were presented to the DSMB
and NHLBI on September 18, 2013 (Figure 1). The total
number of primary events was 671 (8), which
conferred >85% power to detect a relative difference
in event rates of 20% between the 2 treatment arms.
Potent ia l causes of geograph ic d iscrepanc ies .
In TOPCAT, 4 of the 6 countries exhibited relatively
similar patient characteristics and event rates, as well
as favorable effects of spironolactone treatment. Data
from the 2 Eastern European countries differed from
the 4 countries in the Americas, but also from each
other. The Russian cohort was dominated by clinical
presentations of ischemic heart disease, a common
cause of HFpEF, and patients may have been symp-
tomatic (dyspneic) due to ischemia rather than HF.
An increased prevalence of an ischemic etiology in
Eastern European HFpEF patients that was known
unofﬁcially during the TOPCAT trial was eventually
published for the I-PRESERVE and CHARM-Preserved
patient populations (15). It is therefore possible that
ineffectiveness of spironolactone as an anti-ischemic
agent, rather than lack of efﬁcacy against HFpEF,
might have contributed to the TOPCAT results in
Russia.
A predominance of ischemic heart disease
symptoms, however, was apparently not the issue
in patients enrolled in the Republic of Georgia, who
from the beginning of the trial had a very low event
rate and little evidence for HF based on signs and
symptoms or random NP measurements. The lack of
any treatment effect in these patients may well
have been due to the fact that HF was either absent
or much milder than in those enrolled in the
Americas.
Although study drug compliance did not appear to
account for the lack of treatment effect in Russia and
Georgia, as these countries reported using higher
doses of both spironolactone and placebo (11), in the
spironolactone arm, there was a substantially higher
incidence of hyperkalemia and elevations in serum
creatinine in the Americas than in Russia and Georgia
(11). This was interpreted as a “lack of pharmacologic
effect” in Russian and Georgian patients (11), but it
could also be due to the absence of actual study drug
consumption. However, Russian and Georgian pa-
tients had an increase in gynecomastia in thespironolactone versus the placebo arm (11), indicating
they were likely taking study medication. Gyneco-
mastia in the absence of marked hyperkalemia has
been observed in another spironolactone versus pla-
cebo HFpEF study (16) and could be characteristic of a
subcohort of patients. These pharmacodynamic
adverse event data were not reviewed by country
during the trial by the DSMB, although they were
being tracked monthly for the entire trial. Country-
speciﬁc adverse events and severe adverse events
within their standard regulatory organ system
groupings were tracked by the DSMB, and no obvious
differences between countries or regions were noted
in any review.
LESSONS LEARNED AND
RECOMMENDATIONS FOR FUTURE TRIALS
LESSONS LEARNED. Whereas the country-speciﬁc
and regional heterogeneity in TOPCAT could be
viewed as expected statistical variation in a large
multinational trial (1,3), the differences in patient
characteristics, lower event rates, lack of certain drug
class-related pharmacodynamic effects (11), and
complete lack of treatment effect in Russia and
Georgia compared with the other regions strongly
suggest that more than the play of chance occurred.
Enro l lment issues . Because of the difﬁculty in
identifying the phenotype (17) and other issues,
enrollment of patients into HFpEF clinical trials can
be challenging. Consequently, in HFpEF trials, the
pressure to enroll at a projected rate versus the
imperative to conﬁne enrollment to the target popu-
lation is even more in conﬂict than usual. TOPCAT
started behind schedule, and once begun, there was
brisk enrollment from 2 countries where data ulti-
mately proved to be qualitatively problematic. By
the time it was appreciated that there were serious
issues with patient characteristics and event rates in
patients from Russia and Georgia, both countries had
enrolled substantial numbers of subjects. The lesson
learned here is that during the early as well as the
later phases of trial enrollment, recruitment from 1 or
2 regions or sites should not dominate, and patient
characteristics should be monitored carefully to
identify potential regional irregularities in study
subpopulations.
What you see ear ly may be what you get late .
The discrepant patterns of patient characteristics and
event rates in Russia or Georgia were present from the
ﬁrst opportunity to observe them and persisted
throughout the trial. Although it is well known that
treatment effects can vary during a trial, ﬂuctuations
in patient characteristics and overall event rates may
TABLE 2 Overall and Country-Speciﬁc HR and Total Number
of Primary Events Conﬁrmed by Adjudication at the 75%
Interim Analysis
HR
Number of Subjects
With Conﬁrmed
Primary Event
United States 0.786 230
Canada 0.642 49
Russia 0.950 62
Republic of Georgia 0.993 14
Argentina 0.745 18
Brazil 0.473 9
Overall 0.792 382
HR ¼ hazard ratio.
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187not exhibit such plasticity. It would seem prudent to
place considerable weight on early observations that
remain consistent, particularly if they could threaten
trial integrity.
Country- and reg ion-spec iﬁc event rates need to
be carefu l ly fo l lowed and may demand dissem-
inat ion beyond the DSMB. At no time during the
trial did the aggregate event rate depart from expec-
tations, and this was periodically communicated to
the Steering Committee. Country-speciﬁc event rates
were not speciﬁcally disclosed by the DSMB to the
Steering Committee, and it is possible that such in-
formation would have triggered earlier or more
deﬁnitive corrective actions. Continuing to enroll in a
region where the event rate is inadequate to assess
the tested treatment effect is questionable and, at a
minimum, should be brought to a steering commit-
tee’s attention. In TOPCAT, this information was
communicated only indirectly. Once the DSMB was
conﬁdent there was an issue, direct reports of the
actual aggregate event rates to the trial’s leadership
might have resulted in different management
decisions.
In a la rge , mult i center c l in i ca l t r ia l , change i s
d i fﬁcu l t but not chang ing may be fata l . Both as-
pects of this popular management trope apply to large
multicenter trials, especially multinational ones. For
various reasons that include regulatory compliance
and site burden, investigators are understandably
reluctant to make substantive changes in clinical
protocols during a trial. Yet there are often de-
velopments in trials that need major adjustments or
changes in overall approach. In TOPCAT, the ﬁrst
opportunity for geographic disparity corrective mea-
sures occurred at the review in April 2009, with the
conﬁrmation that event rates were extremely low in
Georgia and low in Russia. The DSMB recommenda-
tion at the time was continued enhanced enrollmentof patients in North America. Thereafter, an ad hoc NP
study strongly suggesting much less advanced HF in
Russia or Georgia plus persistence of the lower event
rates and the trial’s response of accelerated site
monitoring did not lead to any apparent change in the
clinical characteristics of randomized patients or to
curtailment of enrollment. In fact, Georgia ﬁnished at
200% of its enrollment target, and after April 2009,
another 666 patients were enrolled in Russia and
Georgia. If those patients had been enrolled in the
Americas, it could be speculated that the trial may
have been positive.
Requi rement of an elevated B-type natr iu ret i c
pept ide measurement in future HFpEF tr ia l s? As
referenced in the trial overview section, the HR in
the 981 patients enrolled with an elevated BNP or
NT-proBNP was highly statistically signiﬁcant at 0.65
compared with the nonsigniﬁcant HR in the 2,464
patients enrolled based on a history of HF hospitali-
zation (8,11). In HFpEF an elevated NP level adds
precision to the HF diagnosis and provides objective
evidence for a certain degree of HF severity (13,14).
NP assays are now available in virtually all regions
where clinical trial capability exists. However, in
I-PRESERVE, a treatment effect of the angiotensin-
receptor blocker irbesartan was only observed in
patients with randomization NT-proBNP levels below
the median of 339 pg/ml (18), a value below the
TOPCAT qualifying value of 360 pg/ml. In addition, in
TOPCAT, NP levels are not easily separated from the
geographic disparity issues. Therefore, further anal-
ysis of the TOPCAT data will be required to add
credence to any recommendation regarding baseline
NP levels and eligibility criteria for future HFpEF
trials.
Adapt ive increases in tr ia l sample s i ze can be
prospect ive ly des igned and may increase the
probabi l i ty of success . Despite the country-/
region-speciﬁc issues in TOPCAT, it is possible that
the trial could have been salvaged based on infor-
mation available at the 75% of total events interim
analysis. Speciﬁcally, when a late/pre-speciﬁed
interim analysis has a HR within certain boundaries
termed the “promising zone” the sample size may be
increased without inﬂating type 1 error (19,20). In
general the promising zone band encompasses con-
ditional powers between 50% and 80% (19,20), which
is where the TOPCAT conditional power calculations
were at the 75% interim. Operationally, the option to
increase sample size by a pre-speciﬁed amount based
on conditional power or Bayesian predictive proba-
bilities needs to be prospectively deﬁned, and the
sponsor must be willing to support the increase in
trial budget to account for the sample size increase.
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188An increase in sample size, by for example 25%, could
have been a recommendation by the DSMB if this
“adaptive” strategy had been incorporated into the
design. However, NHLBI budget limitations, overall
trial fatigue, and the downside of extended follow-up
of already enrolled patients all would have argued
against such an approach. Notably the 75% interim
analysis overall HR was substantially lower (0.79)
(Table 2) than the ﬁnal result of 0.89, and so some of
these negative factors including an increasingly high
study drug discontinuation rate that reached 34% in
the spironolactone arm at trial completion (8)
(Supplemental Appendix) may have adversely
affected outcomes between the 75% interim and
completion of the trial. If in fact any additional
enrolled patients would have had outcomes similar to
those recorded between the 75% interim analysis and
the end of the trial, the additional increase in sample
size would not have rendered the trial positive.
RECOMMENDATIONS FOR FUTURE TRIALS. Based
on these issues and discussion, the TOPCAT DSMB
has the following suggestions for multinational clin-
ical trials:
1. Launch the trial in a variety of geographic juris-
dictions, and do not allow 1 or 2 geographic areas
to dominate early (or late) enrollment.
2. Follow country- and region-speciﬁc patient char-
acteristics and aggregate event rates carefully,
beginning early in the trial; if a country or region
exhibits event rates that are statistically signiﬁ-
cantly lower than the composite of other regions
and especially if this is reinforced by differences in
disease characteristics, bring this to the attention
of Steering Committee leadership.
3. Establish detailed plans for trial surveillance in the
DSMB charter, and at the initiation of the trial,
inform investigators and national leaders of pro-
posed country- and region-speciﬁc analyses of
patient data and requirements for characteristics
of the study population, with the directive that
the trial may be subject to geographic constraintif enrolled patients do not fulﬁll pre-trial assump-
tions and/or are substantially different from other
regions.
4. Incorporate objective measures used to determine
disease presence and severity to the greatest
extent possible in enrollment criteria, particularly
for conditions such as HFpEF where the diagnosis
can be challenging.
CONCLUSIONS
In summary, to paraphrase a popular aphorism from
American football (21), multicenter, multinational
clinical trials are a rough game and often a cruel one.
They require extreme cooperation from groups of in-
dividuals and institutions with experience and skill, a
willingness to adjust to unanticipated circumstances,
and the ability to make difﬁcult decisions. Unantici-
pated developments are to be expected, and pro-
visions can and should be built into trial design to
facilitate identifying and managing them.
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